Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity
Publisher: 'Massachusetts Medical Society'
DOI identifier: 10.1056/nejmoa070812.
Sorry, we are unable to provide the full text but you may find it at the